

DM in pediatric

- T1DM results from deficiency of Insulin bcz of pancreatic β -cells damage
- Median age of onset: 7-15 yr
- 2 peaks
 - 4-6 yr
 - 10-14 yr
- Sudden onset
- Presentation: polyuria, polydipsia, polyphagia, weight loss, DKA
- Goal: 72-180 mg/dL

Natural history

1. preclinical β -cells autoimmunity with progressive defect of Insulin secretion
 2. Abnormal blood sugar, (+) anti bodies, **No symptoms**
 3. Onset of Clinical DM
 4. Honeymoon period
 5. Acute/chronic complications may occur
- * After 80-90% of β -cells are destroyed, Hyperglycemia develops

Etiology

- Autoimmune destruction of β -cells
- Genetic susceptibility + Environmental factors
- 95% of pts have either HLA-DR3 or HLA-DR4
- polygenic inheritance
- Viruses, Toxic chemicals, Early exposure to cow milk in infancy

Autoantibodies

- ICA
 - ICAS1/2
 - GAD
 - IAA
 - ZnT8A
- These can be detected mo to yrs prior to clinical onset

LADA

- Latent Autoimmune Diabetes of Adult
- Late 30s & early 40s
- Less aggressive
- Presentation betw T1DM & T2DM

Physical examination


- Usually normal
- DKA: Kussmaul breathing, signs of dehydration, hypotension, altered mental status

Honeymoon period

Period of stable blood glucose, after first weeks of therapy, continues for 3-6 mo

MODY

- Genetic defect of β -cells function
- Monogenic
- AD
- 9-25 yr



Labs

- FBG ≥ 126 mg/dL in more than one occasion
- RBG ≥ 200 mg/dL + symptoms
- HbA1c $\geq 6.5\%$
- Islet cell autoantibodies
- Blood gas & ketones
- C-peptide
 - Low: Confirm Dx
 - Normal: pt with T1DM may have normal C-peptide up to 2 yrs
- Screening for associated conditions

DDx

T2DM, MODY, Endocrine disorders, Drugs (Thiazides), chronic pancreatitis, cystic fibrosis, Prader-Willi syndrome, Non-diabetic Glycosuria

Neonatal DM


- Monogenic defect, <6 mo
- Mutation in KCNJ11, ABCC8

Insulin

- Anabolic hormone
- Carbohydrates: \uparrow utilization of Glucose, \uparrow Glycogen synthesis, \downarrow Gluconeogenesis, \downarrow Glycogenolysis
- Fat: \uparrow Lipogenesis, \downarrow Lipolysis
- Protein: \uparrow protein synthesis, \downarrow proteolysis

Absence of Insulin

- \uparrow Lipolysis \rightarrow Weight loss (+ loss of calories by Glycosuria), ketone bodies
- \uparrow proteolysis \rightarrow Muscle wasting & fatigue
- \uparrow Glycogenolysis & \uparrow gluconeogenesis \rightarrow Hyperglycemia + Glycosuria



- * ketone bodies: β -hydroxybutyrate, Acetoacetate, Acetone
- Glycosuria: Glucose level exceeds renal threshold 160-190 mg/dL
- Glycosuria \rightarrow Osmotic diuresis (+ loss in Na^+ , K^+) \rightarrow Dehydration & Polydipsia

Comorbid conditions of T1DM

- Autoimmune thyroid disease (Mainly Hashimoto), screen for anti-TPO antibodies
- Celiac disease: screen for anti-ETG antibodies
- Addison disease

Dawn phenomenon

- Hyperglycemia between 5-9 am without preceding hypoglycemia
- Due to clearance of Insulin & Nocturnal increase in GH
- TE: \uparrow Evening dose of Insulin

Somogy phenomenon

- Hypoglycemia episode followed by Hyperglycemia
- Insulin induced hypoglycemia followed by outpouring of counterregulatory hormones
- TE: \downarrow Insulin dose